Xiao Xu

Dr. Xu has more than 20 years of experience as an executive in the biotech industry. Dr. Xu was a co-founder, president and CEO of ACEA Biosciences (acquired by Agilent in 2018) and ACEA Therapeutics (acquired by Sorrento Therapeutics in 2021). He joins Sorrento Therapeutics after the acquisition and continues functioning as President of ACEA, a subsidiary of Sorrento Therapeutics.

He has been managing and responsible for ACEA innovative drug pipeline development, clinical studies, and cGMP manufacturing facility.

He was the co-inventor of innovative label-free cell-based assay technology and was responsible for technology/product development and business partnership with Roche Diagnosis, global commercialization of ACEA’s proprietary technology and products, and $250 million Agilent acquisition of ACEA Biosciences.

He has been a staff investigator and research scientist at Gladstone Institutes, The Scripps Research Institute and US Centers for Disease Control and Prevention. He owns over 50 US patents and patent applications and has published over 60 research articles in international journals, including Science, PNAS, Nature Biotechnology, and Chemistry and Biology.